Written by
Phil Grainger
Bhvita Jani
Share article:
Siemens Healthineers has made a binding offer to acquire the diagnostic arm of Novartis’ Advanced Accelerator Applications (AAA) for above $223M. The deal, which will enhance Siemens Healthineers’ portfolio with 14 additional manufacturing sites for the radioactive isotope fluorine-18 across France, Spain, Portugal, Italy, Germany and Switzerland, is expected to close by the end of this year.
Why we are covering this topic
- With this deal, Siemens will acquire Europe’s second largest cyclotron network, used to manufacture radioactive compounds for diagnostics and treatment of cancer and neurodegenerative diseases.
- By expanding its cyclotron network within Europe, Siemens Healthineers improves its position within radiopharmaceuticals and positions itself to capitalise on the anticipated growth in the PET segment.
Why it matters
- With market conditions becoming increasingly challenging and competitive, medical imaging equipment vendors are under considerable pressure to find new growth opportunities.
- Molecular imaging, and PET in particular, looks to be a significant growth engine for the few vendors that have the resources to invest in the technology.
Read the full insight with a Signify Premium Insights - Medical Imaging subscription
